# Pregene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pregene

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.pregene.com
- Total disclosed funding: $21M
- Latest round: Series B (Nov 16, 2020)
- Investors on record: 5

## About

Established in 2012 and based in Shenzhen, China, Pregene operates as a CAR-T drug developer that focuses on the developing of new drugs. It acquired ISO9001 quality management system certification. In March 2020, the company obtained its first implicit clinical trial approval. In November 2020, Pregene raised CNY 140 million in series B funding led by new investor Haier Capital. In July 2023, the company was listed on the New Three Board.

The company mainly fused cell drug and nano antibody drugs. Products include CAR-T cell drugs, TCR-T cell injections, CAR-NK drugs, stem cell drugs, and PRG1801. CAR-T cell drug indications cover multiple therapeutic areas such as hematological tumors, solid tumors, and autoimmune diseases. TCR-T is a Class 1 therapeutic biological product used to treat unresectable, recurrent, or metastatic soft tissue sarcomas.

The company generates revenue by providing fused cell drug and nano antibody drugs.

## Funding rounds

- Series B, Nov 16, 2020, $21M — CASH Capital, Hunan Hi-Tech Venture Capital, Haier Capital, Huapont Life Science
- Series B, May 3, 2018 — CASH Capital
- Series A, Jul 22, 2017 — Shenzhen Guozhong Venture Capital

## Investors

- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series B
- Hunan Hi-Tech Venture Capital (https://capitalatlas.ai/funds/hunan-hi-tech-venture-capital) — Series B
- Haier Capital (https://capitalatlas.ai/funds/haier-capital) — Series B
- Huapont Life Science — Series B